News Releases

January 16, 2017

Positive impact. That’s always been the measure of our work. In 2016 we held fast to that standard—delivering sound science, innovative technologies, and evidence-based programs that make a meaningful difference for our clients, and for the communities and people they serve.

January 10, 2017

Treatment patterns for metastatic Colorectal Cancer (mCRC) patients have changed considerably over the last decade since the introduction of new chemotherapies and targeted biologics. These treatments are often administered in various sequences with limited evidence regarding their cost-...

December 20, 2016

When psychiatrists prescribe a drug treatment to a patient, they monitor how well that treatment is working. Scales designed to measure symptoms of specific diagnoses include threshold levels that reflect a minimum clinically important difference (MCID).

December 12, 2016

This webinar will explore the trends in PRO-related product labeling and highlight some key observations found during the review. It will cover what you need to know as you gather evidence about your product, and answer your questions about PRO labeling strategy.

December 5, 2016

Despite an increase in the number of new drugs approved by the US FDA and the increased focus on patient-centered drug development, a recent review showed that the percentage of new drug approvals by the FDA with PRO labeling has declined from about 24% during the period 2006-2010 to 16% between...

December 1, 2016

A well-created budget impact analysis (BIA) can help accurately estimate the potential spend on a new health care treatment. A poorly prepared or missing BIA can lead to disaster.

November 22, 2016

In the face of a growing focus on value and cost effectiveness, authors Stephanie Earnshaw, Nadia Demarteau, and Baudouin Standaert have written a chapter in the newly released book, The Future of Health Economics that introduces innovative new ways to evaluate information for making health care...

November 18, 2016

Infographic. As cost-containment pressures intensify, clinical trial safety and efficacy data alone are no longer adequate to meet the needs of health care decision makers—driving a need for real-world data to demonstrate value of treatments.

November 2, 2016

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its Initiative on US Value Assessment Frameworks Stakeholder Conference, in Washington, DC, USA on September 23, 2016. The one-day meeting was designed to convene stakeholders across all segments of health care to...

October 21, 2016

Psychiatrists and other clinicians should be cautious about allowing patients' genetic information to carry unnecessary weight in their clinical decision making, according to a study published in Value in Health. RTI Health Solutions Senior Research Economist, Marco Boeri, co-authored a study...

October 21, 2016

RTI Health Solutions joins in supporting World Psoriasis Day. This year’s theme is Breaking Barriers for People with Psoriasis. Our researchers are proud to contribute quality research towards helping those with psoriasis gain effective treatments - treatments that can help give patients a...

October 20, 2016

Plaque psoriasis is an inflammatory, chronic skin disease that can have serious negative effects on a patient’s quality of life. Along with physical symptoms, patients report feeling distressed, anxious, depressed, or even suicidal. A study published today in the British Journal of Dermatology...

October 18, 2016

RTI Health Solutions, a business unit of RTI International will join a collaborative led by the Medical Device Innovation Consortium (MDIC) that will work with Parkinson’s patients to determine the benefit and risk tradeoffs they are willing to make for a potential new therapy, and use that...

October 18, 2016

Deepen your understanding of current topics with one of these workshops led by our experts

October 13, 2016

The occurrence of missing PRO data in oncology studies is commonplace. Faulty assumptions about the reasons for the missing data often lead to inadequate analysis and false conclusions.

October 12, 2016

Health-related quality of life (HRQL) is increasingly viewed as a significant endpoint in oncology trials. It’s also valuable for informing clinical practice. But current analyses of HRQL are often mixed. Standard approaches often fail to take into account the more complex causal pathways...

October 12, 2016

In the UK, the provision of new oncology drugs by the National Health Service (NHS) has been a contentious issue for a number of years. In 2011, the original Cancer Drugs Fund (CDF) began providing a way for patients in England to receive cancer drugs not routinely available on the NHS. The fund...

October 3, 2016

In clinical trials, health care researchers are increasingly working to incorporate data that demonstrate health benefits for patients.

September 22, 2016

You have always been able to depend on our team of experts to help you use data from patient-reported outcome (PRO) measures and other clinical outcome assessments (COAs) to understand the impact of disease and demonstrate the drug benefits most important to patients and other stakeholders. To...

September 21, 2016

"ICPE continues to be THE place to learn from others and share what we have learned."

September 16, 2016

The 32nd ICPE in Dublin was a resounding success! So many things to learn, see, and discuss. With so much going on, you might have missed something that you would have liked to see. We've put together a review of our contributions with links so that you can read the abstracts and view the...

September 12, 2016

Based on data collected and analyzed by the Patient-Centered Outcomes Assessment team at RTI-HS, Ari Gnanasakthy then discusses changes in FDA PRO labeling by comparing data reported from 2006-2010 with data from 2011-2015.

August 25, 2016

About one-third of patients with ADHD have an inadequate response to initial stimulant treatment and consequently might be considered for treatment with one of two second-line treatment options—lisdexamfetamine dimesylate (LDX) or atomoxetine. A recent study by two RTI-HS researchers published...

August 25, 2016

This infographic shows important design elements to be mindful of when creating surveys to evaluate educational measures.

August 17, 2016

Theresa Coles, MS, RTI Health Solutions Senior Health Outcomes Analyst, has been awarded the 2016-17 Alvin R. Tarlov & John E. Ware Jr.

Pages